<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05103683</url>
  </required_header>
  <id_info>
    <org_study_id>TORL123-001</org_study_id>
    <nct_id>NCT05103683</nct_id>
  </id_info>
  <brief_title>First in Human Study of TORL-1-23 in Participants With Advanced Cancer</brief_title>
  <official_title>A Phase 1, First in Human, Dose-Escalation Study of TORL-1-23 in Participants With Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TORL Biotherapeutics, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Translational Research in Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>TORL Biotherapeutics, LLC</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and&#xD;
      antitumor activity of TORL-1-23 in patients with advanced cancer&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2021</start_date>
  <completion_date type="Anticipated">November 15, 2025</completion_date>
  <primary_completion_date type="Anticipated">November 15, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence and severity of adverse events and serious adverse events</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Incidence and severity of adverse events, serious adverse events, according to NCI-CTCAE Version 5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD)</measure>
    <time_frame>28 Days</time_frame>
    <description>Highest administered dose with &lt; 33% participants experiencing dose limiting toxicity (DLT) in the first 6 DLT evaluable participants</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended Phase 2 Dose (RP2D)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Based on the maximum tolerated dose, cumulative safety, and pharmacokinetic data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Percentage of participants with best response of complete response (CR) or partial response (PR) according to RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Time from CR or PR to objective disease progression or death to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>PFS is defined as the time from the start of the treatment until objective disease progression or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Time from start of treatment to complete response or partial response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1 Year Overall Survival (1YOS)</measure>
    <time_frame>1 year</time_frame>
    <description>Proportion of participants alive at 1 year from the start of treatment to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 Year Overall Survival (2YOS)</measure>
    <time_frame>2 years</time_frame>
    <description>Proportion of participants alive at 2 years from the start of treatment to death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of anti-drug antibody (ADA) Positive Participants</measure>
    <time_frame>up to 2 years</time_frame>
    <description>Immunogenicity will be measured by the number of participants that are ADA positive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration of TORL-1-23 (Cmax)</measure>
    <time_frame>21 days</time_frame>
    <description>PK assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Serum Concentration of TORL-1-23 (Cmin)</measure>
    <time_frame>21 days</time_frame>
    <description>PK assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Serum Concentration of TORL-1-23 at Steady State (Cmax,ss)</measure>
    <time_frame>63 days</time_frame>
    <description>PK assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Minimum Serum Concentration of TORL-1-23 at Steady State (Cmin,ss)</measure>
    <time_frame>63 days</time_frame>
    <description>PK assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Maximum Serum Concentration of TORL-1-23 (Tmax)</measure>
    <time_frame>21 days</time_frame>
    <description>PK assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Minimum Serum Concentration of TORL-1-23 (Tmin)</measure>
    <time_frame>21 days</time_frame>
    <description>PK Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of Minimum Serum Concentration of TORL-1-23 at Steady State (Tmin,ss)</measure>
    <time_frame>63 days</time_frame>
    <description>PK Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal Half-life (t1/2) of Serum TORL-1-23</measure>
    <time_frame>63 days</time_frame>
    <description>PK Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the Serum Concentration-Time curve from the time of dosing to the last measurable concentration (AUClast) for TORL-1-23</measure>
    <time_frame>21 days</time_frame>
    <description>PK Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the Serum Concentration-Time curve from the time of dosing extrapolated to time infinity (AUCinf) for TORL-1-23</measure>
    <time_frame>63 days</time_frame>
    <description>PK Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent volume of distribution during the terminal phase (Vz) of TORL-1-23</measure>
    <time_frame>63 days</time_frame>
    <description>PK Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance (CL) of TORL-1-23</measure>
    <time_frame>63 days</time_frame>
    <description>PK Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation ratio (Rac) of TORL-1-23</measure>
    <time_frame>63 days</time_frame>
    <description>PK Assessment</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Advanced Solid Tumor</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Endometrial Cancer</condition>
  <arm_group>
    <arm_group_label>Monotherapy Dose Dose Finding - Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TORL-1-23</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion as Monotherapy - Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TORL-1-23</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TORL-1-23</intervention_name>
    <description>antibody drug conjugate (ADC)</description>
    <arm_group_label>Expansion as Monotherapy - Part 2</arm_group_label>
    <arm_group_label>Monotherapy Dose Dose Finding - Part 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Advanced solid tumor&#xD;
&#xD;
          -  Measurable disease, per RECIST v1.1&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1&#xD;
&#xD;
          -  Adequate organ function&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Has not recovered [recovery is defined as NCI CTCAE, version 5.0, grade â‰¤1] from the&#xD;
             acute toxicities of previous therapy, except treatment-related alopecia or laboratory&#xD;
             abnormalities otherwise meeting eligibility requirements&#xD;
&#xD;
          -  Received prior chemotherapeutic, investigational, or other therapies for the treatment&#xD;
             of cancer within 14 days with small molecule and within 28 days with biologic before&#xD;
             the first dose of TORL-1-23&#xD;
&#xD;
          -  Progressive or symptomatic brain metastases&#xD;
&#xD;
          -  Serious, uncontrolled medical disorder, nonmalignant systemic disease, or active,&#xD;
             uncontrolled infection&#xD;
&#xD;
          -  History of significant cardiac disease&#xD;
&#xD;
          -  History of myelodysplastic syndrome (MDS) or AML&#xD;
&#xD;
          -  History of another cancer within 3 years before Day 1 of study treatment, with the&#xD;
             exception of basal or squamous cell carcinoma of the skin that has been definitively&#xD;
             treated. A history of other malignancies with a low risk of recurrence, including&#xD;
             appropriately treated ductal carcinoma in situ (DCIS) of the breast and prostate&#xD;
             cancer with a Gleason score less than or equal to 6, are also not excluded&#xD;
&#xD;
          -  If female, is pregnant or breastfeeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Letrent, PharmD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>TORL Biotherapeutics, LLC</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Stephen Letrent, PharmD, PhD</last_name>
    <phone>858-342-6652</phone>
    <email>stephen.letrent@torlbio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UCLA - JCCC Clinical Research Unit</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <contact>
      <last_name>Gottfried Konecny, MD</last_name>
      <phone>310-794-4955</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 21, 2021</study_first_submitted>
  <study_first_submitted_qc>October 21, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 2, 2021</study_first_posted>
  <last_update_submitted>October 21, 2021</last_update_submitted>
  <last_update_submitted_qc>October 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

